Table 1.
NETest scores, PRRT predictive quotient (PPQ) and Chromogranin A (CgA) values after PRRT in “RECIST”-responders and “non-responders”
| Total Patients (n=157) | Patients Assessed (n=122) | ||||
|---|---|---|---|---|---|
| RECIST Predicted Response | Responders (n=83) |
Non-Responders (n=39) |
|||
| NETest | |||||
| NETest alterations to PRRT | N | % | N | % | |
| NETest decrease | 82 | 99 | 10 | 26 | |
| NETest increase | 1 | 1 | 29 | 74 | |
| Accuracy (alterations) | 111/122 | 91% | |||
| Follow-up NETest after PRRT | N | % | N | % | |
| NETest ≤40 (“stable”) | 77 | 93 | 8 | 20 | |
| NETest >40 (“progressive”) | 11 | 7 | 31 | 80 | |
| Accuracy (category) | 108/122 | 89% | |||
| NETest overall accuracy | N | % | |||
| 119/122 | 98% | ||||
| PPQ Predicted Responders | PPQ +ve (n=81) |
PPQ -ve (n=41) |
|||
| NETest alterations to PRRT | %±SD | ||||
| Percentage change | −46±3 | ±75±19 | |||
| NETest levels | Mean±SD | ||||
| Pre-PRRT | 61±22 | 54±27 | |||
| Pre-IV cycle | 35±20 | 59±27 | |||
| At follow-up | 29±12 | 64±22 | |||
| Follow-up NETest after PRRT | N | % | N | % | |
| NETest ≤40 (“stable”) | 75 | 92 | 8 | 20 | |
| NETest >40 (“progressive”) | 7 | 8 | 32 | 80 | |
| PPQ Prediction Accuracy/RECIST | |||||
| RECIST-based responder | 80 | 99 | 2 | 5 | |
| RECIST-based no responder | 1 | 1 | 38 | 95 | |
| PPQ concordance | N | % | |||
| 118/122 | 97% | ||||
| Patients Assessed (n=112) | |||||
| CgA Predicted Responders/RECIST |
Responders (n=76) |
Non-Responders (n=36) |
|||
| CgA alterations during PRRT | N | % | N | % | |
| CgA decrease | 39 | 51 | 17 | 47 | |
| CgA increase | 37 | 49 | 19 | 53 | |
| CgA overall accuracy | N | % | |||
| All patients | 58/112 | 52 | |||